• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction.CD40-CD40L共刺激蛋白-蛋白相互作用的小分子抑制剂
J Med Chem. 2017 Nov 9;60(21):8906-8922. doi: 10.1021/acs.jmedchem.7b01154. Epub 2017 Oct 25.
2
Design, Synthesis, and Evaluation of Novel Immunomodulatory Small Molecules Targeting the CD40⁻CD154 Costimulatory Protein-Protein Interaction.新型靶向 CD40-CD154 共刺激蛋白-蛋白相互作用的免疫调节小分子的设计、合成与评价。
Molecules. 2018 May 11;23(5):1153. doi: 10.3390/molecules23051153.
3
The role of CD40 ligand in costimulation and T-cell activation.CD40配体在共刺激和T细胞活化中的作用。
Immunol Rev. 1996 Oct;153:85-106. doi: 10.1111/j.1600-065x.1996.tb00921.x.
4
Murine Fibroblastic Reticular Cells From Lymph Node Interact With CD4+ T Cells Through CD40-CD40L.来自淋巴结的小鼠成纤维网状细胞通过CD40-CD40L与CD4+T细胞相互作用。
Transplantation. 2015 Aug;99(8):1561-7. doi: 10.1097/TP.0000000000000710.
5
Small-molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction.小分子共刺激阻断:CD40-CD154 相互作用的有机染料抑制剂。
J Mol Med (Berl). 2009 Nov;87(11):1133-43. doi: 10.1007/s00109-009-0519-3. Epub 2009 Aug 26.
6
Rapid induction of a novel costimulatory activity on B cells by CD40 ligand.CD40配体对B细胞新型共刺激活性的快速诱导。
Curr Biol. 1995 Nov 1;5(11):1303-11. doi: 10.1016/s0960-9822(95)00257-0.
7
Organic dyes as small molecule protein-protein interaction inhibitors for the CD40-CD154 costimulatory interaction.有机染料作为小分子蛋白-蛋白相互作用抑制剂用于 CD40-CD154 共刺激相互作用。
J Mol Recognit. 2010 Jan-Feb;23(1):65-73. doi: 10.1002/jmr.969.
8
Effective and specific inhibition of the CD40-CD154 costimulatory interaction by a naphthalenesulphonic acid derivative.一种萘磺酸盐衍生物有效且特异性地抑制 CD40-CD154 共刺激相互作用。
Chem Biol Drug Des. 2010 Oct;76(4):305-13. doi: 10.1111/j.1747-0285.2010.01014.x. Epub 2010 Jul 15.
9
Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling.肿瘤坏死因子受体超家族成员CD40、Fas和肿瘤坏死因子相关凋亡诱导配体受体2(TRAILR2)之间的异源寡聚化调节CD40信号传导。
Cell Death Dis. 2017 Feb 9;8(2):e2601. doi: 10.1038/cddis.2017.22.
10
Human CD14hi monocytes and myeloid dendritic cells provide a cell contact-dependent costimulatory signal for early CD40 ligand expression.人源 CD14hi 单核细胞和髓系树突状细胞为早期 CD40L 表达提供细胞接触依赖性共刺激信号。
Blood. 2011 Feb 3;117(5):1585-94. doi: 10.1182/blood-2008-01-130252. Epub 2010 Jul 15.

引用本文的文献

1
Integrative bioinformatics frameworks for abdominal aortic aneurysm using GWAS meta-analysis, biological network construction, and structural modeling.使用全基因组关联研究荟萃分析、生物网络构建和结构建模的腹主动脉瘤综合生物信息学框架。
Sci Rep. 2025 Jul 1;15(1):22331. doi: 10.1038/s41598-025-07989-1.
2
Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases.针对免疫介导的炎症性疾病中的 TNF/TNFR 超家族。
J Exp Med. 2024 Nov 4;221(11). doi: 10.1084/jem.20240806. Epub 2024 Sep 19.
3
Development of SARS-CoV-2 entry antivirals.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)进入抑制剂的研发。
Cell Insight. 2024 Jan 30;3(1):100144. doi: 10.1016/j.cellin.2023.100144. eCollection 2024 Feb.
4
Small molecules targeting protein-protein interactions for cancer therapy.靶向蛋白质-蛋白质相互作用的小分子用于癌症治疗。
Acta Pharm Sin B. 2023 Oct;13(10):4060-4088. doi: 10.1016/j.apsb.2023.05.035. Epub 2023 Jun 1.
5
Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction from a Chemical Space of Privileged Protein Binders.来自特权蛋白结合剂化学空间的新冠病毒刺突蛋白-血管紧张素转换酶2蛋白-蛋白相互作用的广谱小分子抑制剂
Pharmaceuticals (Basel). 2022 Aug 30;15(9):1084. doi: 10.3390/ph15091084.
6
Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19.亚甲蓝是一种非特异性蛋白质-蛋白质相互作用抑制剂,具有重新用作COVID-19抗病毒药物的潜力。
Pharmaceuticals (Basel). 2022 May 18;15(5):621. doi: 10.3390/ph15050621.
7
B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications.动脉粥样硬化中的B细胞:机制与潜在临床应用
JACC Basic Transl Sci. 2021 Jun 28;6(6):546-563. doi: 10.1016/j.jacbts.2021.01.006. eCollection 2021 Jun.
8
Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2.冠状病毒刺突的小分子抑制剂:作为 SARS-CoV-2 病毒附着和进入的 ACE2 蛋白-蛋白相互作用抑制剂。
ACS Infect Dis. 2021 Jun 11;7(6):1519-1534. doi: 10.1021/acsinfecdis.1c00070. Epub 2021 May 12.
9
Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction-a Mechanism that can Contribute to its Antiviral Activity Against COVID-19.亚甲蓝抑制严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白与血管紧张素转换酶2(ACE2)的蛋白质-蛋白质相互作用——这一机制可能有助于其对2019冠状病毒病(COVID-19)的抗病毒活性。
Front Pharmacol. 2021 Jan 13;11:600372. doi: 10.3389/fphar.2020.600372. eCollection 2020.
10
Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials.近年来,蛋白质-蛋白质相互作用调节剂的研发取得了进展:作用机制和临床试验。
Signal Transduct Target Ther. 2020 Sep 23;5(1):213. doi: 10.1038/s41392-020-00315-3.

本文引用的文献

1
Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.2001年至2010年间美国食品药品监督管理局批准的新型治疗药物的上市后安全事件
JAMA. 2017 May 9;317(18):1854-1863. doi: 10.1001/jama.2017.5150.
2
The Ecstasy and Agony of Assay Interference Compounds.分析干扰化合物的喜与忧
J Med Chem. 2017 Mar 23;60(6):2165-2168. doi: 10.1021/acs.jmedchem.7b00229. Epub 2017 Feb 28.
3
Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection.Fc沉默抗CD154结构域抗体有效预防非人灵长类动物肾移植排斥反应。
Am J Transplant. 2017 May;17(5):1182-1192. doi: 10.1111/ajt.14197. Epub 2017 Feb 25.
4
Glucolipotoxicity initiates pancreatic β-cell death through TNFR5/CD40-mediated STAT1 and NF-κB activation.糖脂毒性通过TNFR5/CD40介导的STAT1和NF-κB激活引发胰腺β细胞死亡。
Cell Death Dis. 2016 Aug 11;7(8):e2329. doi: 10.1038/cddis.2016.203.
5
Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.小分子,大目标:药物发现面临蛋白-蛋白相互作用挑战。
Nat Rev Drug Discov. 2016 Aug;15(8):533-50. doi: 10.1038/nrd.2016.29. Epub 2016 Apr 11.
6
Pioneering apoptosis-targeted cancer drug poised for FDA approval.首款靶向凋亡的癌症药物有望获美国食品药品监督管理局批准。
Nat Rev Drug Discov. 2016 Mar;15(3):147-9. doi: 10.1038/nrd.2016.23.
7
The Contribution of CD40/CD40L Axis in Inflammatory Bowel Disease: An Update.CD40/CD40L轴在炎症性肠病中的作用:最新进展
Front Immunol. 2015 Oct 16;6:529. doi: 10.3389/fimmu.2015.00529. eCollection 2015.
8
Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions.在开发靶向蛋白质-蛋白质相互作用的抑制剂过程中克服化学、生物学和计算方面的挑战。
Chem Biol. 2015 Jun 18;22(6):689-703. doi: 10.1016/j.chembiol.2015.04.019.
9
Prevention and reversal of type 1 diabetes--past challenges and future opportunities.预防和逆转 1 型糖尿病——过去的挑战与未来的机遇。
Diabetes Care. 2015 Jun;38(6):997-1007. doi: 10.2337/dc15-0349.
10
TNF superfamily protein-protein interactions: feasibility of small- molecule modulation.肿瘤坏死因子超家族蛋白-蛋白相互作用:小分子调节的可行性
Curr Drug Targets. 2015;16(4):393-408. doi: 10.2174/1389450116666150223115628.

CD40-CD40L共刺激蛋白-蛋白相互作用的小分子抑制剂

Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction.

作者信息

Chen Jinshui, Song Yun, Bojadzic Damir, Tamayo-Garcia Alejandro, Landin Ana Marie, Blomberg Bonnie B, Buchwald Peter

机构信息

Diabetes Research Institute, ‡Molecular and Cellular Pharmacology, and §Microbiology and Immunology, Miller School of Medicine, University of Miami , Miami, Florida 33136, United States.

出版信息

J Med Chem. 2017 Nov 9;60(21):8906-8922. doi: 10.1021/acs.jmedchem.7b01154. Epub 2017 Oct 25.

DOI:10.1021/acs.jmedchem.7b01154
PMID:29024591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5823691/
Abstract

Costimulatory interactions are required for T cell activation and development of an effective immune response; hence, they are valuable therapeutic targets for immunomodulation. However, they, as all other protein-protein interactions, are difficult to target by small molecules. Here, we report the identification of novel small-molecule inhibitors of the CD40-CD40L interaction designed starting from the chemical space of organic dyes. For the most promising compounds such as DRI-C21045, activity (IC) in the low micromolar range has been confirmed in cell assays including inhibition of CD40L-induced activation in NF-κB sensor cells, THP-1 myeloid cells, and primary human B cells as well as in murine allogeneic skin transplant and alloantigen-induced T cell expansion in draining lymph node experiments. Specificity versus other TNF-superfamily interactions (TNF-R1-TNF-α) and lack of cytotoxicity have also been confirmed at these concentrations. These novel compounds provide proof-of-principle evidence for the possibility of small-molecule inhibition of costimulatory protein-protein interactions, establish the structural requirements needed for efficient CD40-CD40L inhibition, and serve to guide the search for such immune therapeutics.

摘要

共刺激相互作用是T细胞活化和有效免疫反应发展所必需的;因此,它们是免疫调节中有价值的治疗靶点。然而,与所有其他蛋白质-蛋白质相互作用一样,它们很难被小分子靶向。在此,我们报告从有机染料的化学空间出发设计出的新型CD40-CD40L相互作用小分子抑制剂的鉴定。对于最有前景的化合物,如DRI-C21045,在细胞实验中已证实其活性(IC)在低微摩尔范围内,包括在NF-κB传感器细胞、THP-1髓样细胞和原代人B细胞中抑制CD40L诱导的活化,以及在小鼠同种异体皮肤移植和引流淋巴结实验中抑制同种异体抗原诱导的T细胞扩增。在这些浓度下,还证实了其对其他TNF超家族相互作用(TNF-R1-TNF-α)的特异性和无细胞毒性。这些新型化合物为小分子抑制共刺激蛋白质-蛋白质相互作用的可能性提供了原理验证证据,确定了有效抑制CD40-CD40L所需的结构要求,并有助于指导此类免疫疗法的探索。